Prognostic and diagnostic significance of preoperative Jumonji domain‑containing 6 antibodies in colorectal cancer

Yoshida, Kimihiko; Hiwasa, Takaki; Ito, Masaaki; Ushigome, Mitsunori; Takizawa, Hirotaka; Li, Shu-Yang; Zhang, Bo-Shi; Iwadate, Yasuo; Funahashi, Kimihiko; Shimada, Hideaki

doi:10.3892/ol.2023.13713

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To generate the expression plasmids for glutathione S-transferase (GST)-fused JMJD6 protein, we integrated JMJD6 cDNA sequence between 1075 and 1834 into the EcoRI/XhoI site of pGEX-4T-1 vector (Cytiva, Marlborough, MA), as previously described [43].…”

Section: Expression and Purification Of Jmjd6 Proteinmentioning

confidence: 99%

JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases

Zhang,

Ito

et al. 2024

Preprint

View full text Add to dashboard Cite

Atherosclerosis is associated with vascular diseases, diabetes, and cancers. The Jumonji C-domain-containing 6 (JMJD6) gene plays an important role in diverse biological processes. In addition, autoantibodies are reportedly useful in the early diagnosis and treatment of many diseases. Here, JMJD6 was identified by serological identification of antigens by recombinant cDNA expression cloning as an antigen recognized by serum IgG from patients with unstable angina pectoris. Then, we performed amplified luminescent proximity homogeneous assay-linked immunosorbent assay using purified recombinant antigens and found elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with atherosclerosis-related diseases including ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers including esophageal cancer (EC), gastric cancer, lung cancer, and mammary cancer, compared with those in healthy donors. The s-JMJD6-Ab levels were closely associated with hypertension, habitual smoking, and the intima-media thickness, an atherosclerosis index. The better postoperative survival status was shown in patients with EC from the JMJD6-Ab-positive group than the negative group, especially from JMJD6-Ab-positive/PD-L1-negative group and JMJD6-Ab-positive/p53-Ab-negative group than JMJD6-Ab-negative/PD-L1-positive group and JMJD6-Ab-negative/p53-Ab-positive group, respectively. Hence, JMJD6 autoantibodies may reflect atherosclerosis severity, thereby a potential biomarker for atherosclerosis-related diseases including ischemic stroke, AMI, DM, and cancers and for predicting EC prognosis.

show abstract

Section: Expression and Purification Of Jmjd6 Proteinmentioning

confidence: 99%

JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases

Zhang,

Ito

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The aberrant expression of JMJD6 has been reported in a wide panel of tumor types such as breast [ 8 ], hepatic [ 9 ], prostate cancer [ 10 ], colorectal [ 11 ] cancer and neuroblastoma [ 12 ]. The tumor expression of JMJD6 was also correlated with treatment resistance [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3/IL-10 axis

Chen,

Wang,

et al. 2023

Oncogene

View full text Add to dashboard Cite

The tumor-associated macrophage (TAM) is the most abundant group of immune cells in the tumor microenvironment (TME), which plays a critical role in the regulation of tumor progression and treatment resistance. Based on different polarization status, TAMs may also induce antitumor immune responses or immunosuppression. The present study identified JMJD6 (Jumonji domain-containing 6) as a novel modulator of TAM activation, the upregulation of which was associated with the immunosuppressive activities of TAMs. JMJD6 deficiency attenuated the growth of both Lewis lung carcinoma (LLC) tumors and B16F10 melanomas by reversing M2-like activation of macrophages, and sensitized tumors to immune checkpoint blockades (ICBs). Moreover, the JMJD6-induced inhibition of M2 polarization was potentially mediated by the STAT3/IL-10 signaling. These findings highlight the regulatory activities of JMJD6 in TAM polarization, and the therapeutic potential of JMJD6/STAT3/IL-10 axis blockades to enhance the efficacy of ICBs in cancer treatment.

show abstract

JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases

Zhang,

Ito

et al. 2024

IJMS

View full text Add to dashboard Cite

Inflammation is closely associated with cerebrovascular diseases, cardiovascular diseases, diabetes, and cancers, and it is accompanied by the development of autoantibodies in the early stage of inflammation-related diseases. Hence, it is meaningful to discover novel antibody biomarkers targeting inflammation-related diseases. In this study, Jumonji C-domain-containing 6 (JMJD6) was identified by the serological identification of antigens through recombinant cDNA expression cloning. In particular, JMJD6 is an antigen recognized in serum IgG from patients with unstable angina pectoris (a cardiovascular disease). Then, the serum antibody levels were examined using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay and a purified recombinant JMJD6 protein as an antigen. We observed elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with inflammation-related diseases such as ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers (including esophageal cancer, EC; gastric cancer; lung cancer; and mammary cancer), compared with the levels in healthy donors. The s-JMJD6-Ab levels were closely associated with some inflammation indicators, such as C-reactive protein and intima–media thickness (an atherosclerosis index). A better postoperative survival status of patients with EC was observed in the JMJD6-Ab-positive group than in the negative group. An immunohistochemical analysis showed that JMJD6 was highly expressed in the inflamed mucosa of esophageal tissues, esophageal carcinoma tissues, and atherosclerotic plaques. Hence, JMJD6 autoantibodies may reflect inflammation, thereby serving as a potential biomarker for diagnosing specific inflammation-related diseases, including stroke, AMI, DM, and cancers, and for prediction of the prognosis in patients with EC.

show abstract

Prognostic and diagnostic significance of preoperative Jumonji domain‑containing 6 antibodies in colorectal cancer

Cited by 3 publications

References 25 publications

JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases

JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases

JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3/IL-10 axis

JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases

Contact Info

Product

Resources

About